Tardive dyskinesia due to Aripiprazole report of 2 cases

Journal of Clinical Psychopharmacology

Volumn 29, Issue 2, 2009, Pages 185-186

  Lungu, Codrin ^a   Aia, Pratibha G ^b   Shih, Ludy C ^c   Esper, Christine D ^b   Factor, Stewart A ^b   Tarsy, Daniel ^c  

^a NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE;

ADULT; ANXIETY DISORDER; BRAIN DEPTH STIMULATION; CASE REPORT; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; DYSTONIA; FEMALE; HUMAN; LETTER; MALE; PRIORITY JOURNAL; TARDIVE DYSKINESIA; TREATMENT DURATION;

ADULT; ANTIPSYCHOTIC AGENTS; DOPAMINE; DYSKINESIA, DRUG-INDUCED; FEMALE; HUMANS; MALE; MIDDLE AGED; PIPERAZINES; QUINOLONES; RECEPTORS, DOPAMINE D2;

EID: 67649345658     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/JCP.0b013e31819a4bd5     Document Type: Letter

References (17)

1. Tarsy D, Baldessarini RJ. Tardive dyskinesia. Annu Rev Med. 1984;35:605-623.
2. Skidmore F, Weiner WJ, Burke R. Neuroleptic induced tardive dyskinesia variants. In: Factor S, Lang A, Weiner W, eds. Drug Induced Movement Disorders. Massachusetts: Blackwell; 2005:257-284.
3. Klawans HL Jr, Rubovits R. An experimental model of tardive dyskinesia. J Neural Transm. 1972;33:235-246.
4. Tarsy D, Baldessarini RJ. Behavioural supersensitivity to apomorphine following chronic treatment with drugs which interfere with the synaptic function of catecholamines. Neuropharmacology. 1974; 13:927-940.
5. Kane JM. Tardive dyskinesia rates with atypical antipsychotics in adults: prevalence and incidence. J Clin Psychiatry. 2004;65(suppl9):16-20.
6. Jeste DV Tardive dyskinesia rates with atypical antipsychotics in older adults. J Clin Psychiatry. 2004;65(suppl 9):21-24.
7. Tarsy D, Baldessarini RJ. Epidemiology of tardive dyskinesia: is risk declining with modern antipsychotics? Mov Disord. 2006;21:589-598.
8. Grunder G, Carlsson A, Wong DF. Mechanism of new antipsychotic medications: occupancy is not just antagonism. Arch Gen Psychiatry. 2003;60:974-977.
9. Kantrowitz JT, Srihari VH, Tek C. Resolution of tardive dyskinesia after addition of aripiprazole to haloperidol depot. J Clin Psychopharmacol. 2007;27:525-526.
10. Lykouras L, Rizos E, Gournellis R. Aripiprazole in the treatment of tardive dyskinesia induced by other atypical antipsychotics. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31:1535-1536.
11. Pinninti NR, Mago R, Adityanjee. Tardive dystonia-associated prescription of aripiprazole. J Neuropsychiatry Clin Neurosci. 2006;18:426-427.
12. Evcimen YA, Evcimen H, Holland J. Aripiprazole-induced tardive dyskinesia: the role of tamoxifen. Am J Psychiatry. 2007;164:1436-1437.
13. Miller del D, Eudicone JM, Pikalov A, et al. Comparative assessment of the incidence and severity of tardive dyskinesia in patients receiving aripiprazole or haloperidol for the treatment of schizophrenia: a post hoc analysis. J Clin Psychiatry. 2007;68: 1901-1906.
14. Lieberman JA. Dopamine partial agonists: a new class of antipsychotic. CNS Drugs. 2004;18:251-267.
15. Friedman JH, Berman RM, Goetz CG, et al. Open-label flexible-dose pilot study to evaluate the safety and tolerability of aripiprazole in patients with psychosis associated with Parkinson's disease. Mov Disord. 2006;21:2078-2081.
16. Correll CU, Leucht S, Kane JM. Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. Am J Psychiatry. 2004;161:14-25.
17. Correll CU, Schenk EM. Tardive dyskinesia and new antipsychotics. Curr Opin Psychiatry. 2008;21:151-156.